Greywolf Therapeutics

Are you aware of the journey a molecule must take before it becomes a medicine? Kreshnik Hoxha, our Head of CMC & Clinical Supply Chain, recently spoke at BOS Manchester 24 to share the steps a humble molecule takes before it transforms into an investigational medicinal product. The talk focused on the interplay between drug polymorphism and biopharmaceutics, and how important it is to validate CMC findings with in vivo data. Our CMC team thoroughly enjoyed this year's event - which seems to get more impressive each year 👏 #drugdevelopment Bio2Business Ltd

"You really need to do something quite fundamentally different to either try and turn-off autoimmune disease or drive responses in oncology - which is why we’ve centered on manipulating that detection event (Signal 1)” Our CEO & Co-founder, Peter Joyce, speaks with Labiotech.eu on their Beyond Biotech podcast about our origins, clinical progress, and the potential of our approach in developing treatments for autoimmune diseases. Listen now 👉 https://lnkd.in/eRwXZQBQ

The week of the Jefferies London Healthcare conference is always an important time for us, and this year has been particularly busy 🐝 The event, which sees global leaders across our industry descend on the city, has grown considerably over the last few years (anyone else see the queues to get in??) and the team met with a record number of partners and investors. It also coincided with the Lifestars and OBN awards evenings, both of which we gratefully attended as finalists. Sadly we didn't manage to win our categories, however the team had an excellent time and are hopeful for next year. Hats off to winners Adaptimmune and Tubulis GmbH 👏 It's been great to connect with so many of you, and be reminded of all the tremendous innovation happening across biotech! #JefferiesHealthcare #EuropeanLifestarsAwards #OBNAwards

We're delighted to share the appointment of Darlene Deptula-Hicks as our new Chief Financial Officer 🎉 She has worked in CFO roles across numerous #biotech and pharmaceutical companies, including F-Star, Normunity, Northern Biologics, Pieris Pharmaceuticals (PIRS) and T2 Biosystems (TTOO), and has a longstanding track record of growing companies and raising capital in public and private equity markets. Welcome to the team 🙌 Read the full release 👉 https://lnkd.in/eiGPukQZ

Greywolf Therapeutics has woken up looking pretty different today - and with good reason. Since founding the company with Tom McCarthy in 2017 (which now feels like a very long time ago!), our excellent team’s research and development has uncovered much about our novel targets and approach, enabling us to radically rethink the potential impact of our antigen modulation technology and how we help people living with disease. 🔬 We started with a focus on cancers, but now also have programs in autoimmunity. Looking further ahead, we are also excited by our technology’s potential in virology. 🧪 We’ve become a clinical-stage company, with our lead oncology program successfully progressing from the lab to the clinic - with plans for our autoimmunity program to follow along in 2025. 🚀 The company has grown to over 40 people across a wide number of disciplines and backgrounds. I’m quite staggered by the team’s fantastic progress - and it’s this progress that we’ve now captured in our new brand and website 👉https://lnkd.in/eFSkgVeB Stay tuned for more exciting news in the next few months!

We’re pleased to welcome Samantha Bucktrout as our new Head of Research 🙌 Sam is an immunologist by training, having completed her PhD at Edinburgh, then post-doc work with Prof. Stephen Miller at Northwestern and Prof. Jeff Bluestone in California. Sam then transitioned into industry, holding senior research positions at Pfizer, the Parker Institute for Cancer Immunotherapy, and Akamis Bio. She loves snowboarding, long walks with the dog, and riding bikes with her husband and son. Sam's extensive leadership experience and deep expertise in immunology and oncology make her a fantastic addition to our team! 🚀

Achieving effective immunity against many cancers is challenging due to a number of factors, including T cell dysfunction and difficulty in identifying targetable epitopes. Wayne Paes will soon be presenting at the Festival of Biologics about how ERAP inhibitors can unmask and up-regulate an entirely novel repertoire of cancer antigens for recognition, helping guide the immune system and reverse T cell exhaustion. More info 👉 https://lnkd.in/gdZDuaR7 #festivalofbiologics 🇨🇭

We are thrilled to welcome back Kreshnik Hoxha, Head of CMC and Clinical Supply Chain at Grey Wolf Therapeutics, as a featured speaker at BOS Manchester 24. During his presentation, Dr Hoxha will discuss the interface between biopharmaceutics, solubility enhancement and API polymorphism, as well as examining the interplay between these parameters in "crystallising" the drug product strategy. Be sure to listen to Dr. Hoxha on 27th November at 12:10 - 12:30pm. View the programme: https://lnkd.in/eZSpS__w

We're back from #ESMO24 🛬 It was great to learn about the new therapeutic approaches for cancer, how the immunotherapy field is progressing, and also connect with a few of you as well! Seeing so many talented researchers, clinicians and scientists take to the stage to present their work always inspires us 🙌

Attention dry cleaners: some gowns and tuxedos will be coming your way! 👗 🎩 The biotech awards season is in full swing and we’re excited to be finalists for: 🏆 Best Established Biotech #OBNAwards 🏆 Series B Raise of the Year #LifestarsAwards Our team, whose dedicated work led to these nominations, are chuffed to be alongside some truly inspiring companies. We look forward to meeting you all at the ceremonies 🥂 Wish us luck!